Business
DICOT: LIB-01 advanced in clinical trials, secured funding, and expanded IP, positioning for growth
DICOT: LIB-01 advanced in clinical trials, secured funding, and expanded IP, positioning for growth
About this update from Dicot Pharma Ab
Strong clinical progress for LIB-01, robust financial position after oversubscribed rights issue, and expanded patent protection marked 2024. Phase 2a trial is fully funded, with results expected mid-2025, and LIB-01 shows promise for additional indications.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.